logo
Plus   Neg
Share
Email

Bayer Announces Placement Of Elanco Shares For $1.6 Bln

Bayer (BAYZF.PK,BAYRY.PK,BYR.L) said that it has placed 54.5 million shares of Elanco Animal Health at a price of $30.25 per share.

Bayer said it will receive gross proceeds of about $1.649 billion. Bayer has granted the underwriters a 30-day option to purchase up to an additional 8.175 million Elanco shares on the same terms and conditions.

Elanco is not selling any shares and will not receive any proceeds from the proposed offering.

Bayer had received 72.9 million Elanco shares, in connection with the completion of Bayer's sale of its Animal Health business unit to Elanco. It represents approximately 15.5 percent of Elanco's outstanding shares.

As previously indicated, Bayer plans to divest the remaining stake in Elanco in due course.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test. AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory...
Follow RTT